2025-04-01 2026-03-31 false Capium Accounts Production 1.1 11248596 2025-04-01 2026-03-31 11248596 bus:FullAccounts 2025-04-01 2026-03-31 11248596 bus:Micro-entities 2025-04-01 2026-03-31 11248596 bus:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 11248596 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 11248596 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 11248596 2025-04-01 2026-03-31 11248596 2026-03-31 11248596 bus:RegisteredOffice 2025-04-01 2026-03-31 11248596 core:WithinOneYear 2026-03-31 11248596 core:AfterOneYear 2026-03-31 11248596 1 2025-04-01 2026-03-31 11248596 bus:Director1 2025-04-01 2026-03-31 11248596 bus:Director1 2026-03-31 11248596 bus:Director1 2024-04-01 2025-03-31 11248596 2024-04-01 11248596 bus:LeadAgentIfApplicable 2025-04-01 2026-03-31 11248596 2024-04-01 2025-03-31 11248596 2025-03-31 11248596 core:WithinOneYear 2025-03-31 11248596 core:AfterOneYear 2025-03-31 11248596 bus:EntityAccountantsOrAuditors 2024-04-01 2025-03-31 11248596 core:PlantMachinery 2025-04-01 2026-03-31 11248596 core:PlantMachinery 2026-03-31 11248596 core:PlantMachinery 2025-03-31 11248596 core:FurnitureFittings 2025-04-01 2026-03-31 11248596 core:FurnitureFittings 2026-03-31 11248596 core:FurnitureFittings 2025-03-31 11248596 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2026-03-31 11248596 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-03-31 11248596 core:CostValuation core:Non-currentFinancialInstruments 2026-03-31 11248596 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 11248596 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2026-03-31 11248596 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2026-03-31 11248596 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2026-03-31 11248596 core:Non-currentFinancialInstruments 2026-03-31 11248596 core:Non-currentFinancialInstruments 2025-03-31 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 11248596
England and Wales
NEWLIFE MEDICAL AESTHETICS LTD
Unaudited Financial Statements
Period of accounts Start date: 01 April 2025 End date: 31 March 2026

NewLife Medical Aesthetics Ltd Statement of Financial Position As at 31 March 2026
|  | 2026 |  | 2025
--- | --- | --- | --- | ---
|  | £ | £ |  | £ | £
Fixed assets |  |  | 55,132 |  |  | 83,454
Current assets |  | 16,638 |  |  | 21,740 |
Creditors: amount falling due within one year |  | (72,409) |  |  | (87,803) |
Net current assets |  |  | (55,771) |  |  | (66,063)
Total assets less current liabilities |  |  | (639) |  |  | 17,391
Creditors: amount falling due after more than one year |  |  | (7,904) |  |  | (20,879)
Provisions for liabilities |  |  | (65) |  |  | (130)
Net assets |  |  | (8,608) |  |  | (3,618)
Capital and reserves |  |  | (8,608) |  |  | (3,618)
NOTES TO THE ACCOUNTS General Information NewLife Medical Aesthetics Ltd is a private company, limited by shares, registered in England and Wales, registration number 11248596, registration address 42 Coombe Lane, London, SW20 0LA. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies Statement of compliance These financial statements have been prepared in compliance with FRS 105 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. Basis of preparation The financial statements have been prepared under the historical cost convention. The financial statements are prepared in sterling which is the functional currency of the company. Going concern basis The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements. Turnover Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts. Cost of sales Cost of sales includes service charges, the cost of supplies and materials used in operations, and commission payable related to sales activities during the reporting period. Tangible fixed assets Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Plant and Machinery | 10% Straight Line
Fixtures and Fittings | 10% Straight Line
2. | Tangible fixed assets
Cost or valuation | Plant and Machinery |  | Fixtures and Fittings |  | Total
| £ |  | £ |  | £
At 01 April 2025 | 215,200 |  | 55,077 |  | 270,277
Additions | - |  | - |  | -
Disposals | - |  | - |  | -
At 31 March 2026 | 215,200 |  | 55,077 |  | 270,277
Depreciation
At 01 April 2025 | 139,325 |  | 48,792 |  | 188,117
Charge for year | 21,520 |  | 5,508 |  | 27,028
On disposals | - |  | - |  | -
At 31 March 2026 | 160,845 |  | 54,300 |  | 215,145
Net book values
Closing balance as at 31 March 2026 | 54,355 |  | 777 |  | 55,132
Opening balance as at 01 April 2025 | 75,875 |  | 6,285 |  | 82,160
3. | Average number of employees Average number of employees during the year was 4 (2025 : 3).
4. | Director’s loan
| Director Loan Account At the year end a balance of £54,762 was owed to the director. The above balance is interest free and no fixed date for repayment.
For the year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Director's responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the micro-entity provisions and FRS 105, the Financial Reporting Standard applicable to the micro-entities regime. The accounts have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The income statement has not been delivered to the Registrar of Companies. The financial statements were approved by the director on 12 August 2026 and were signed by:
-------------------------------- Musharraf Ashraf Director
1